FAQ

Fresenius Medical Care AG is a global healthcare company focused on the treatment of patients with chronic kidney disease. The company specializes in dialysis, a life-sustaining procedure that replaces kidney function when it is permanently impaired.

Fresenius Medical Care combines medical services and medical technology: the company operates dialysis centers where patients receive regular treatment and develops and manufactures the necessary equipment and consumables.
This allows Fresenius Medical Care to cover a key part of the healthcare value chain for kidney patients, from treatment to technical solutions.

Fresenius Medical Care AG was founded in 1996. In that year, the dialysis activities of the German Fresenius Group were merged with the U.S. dialysis provider National Medical Care and established as an independent company.

Fresenius Medical Care AG is headquartered in Bad Homburg vor der Höhe, Germany.

As of December 31, 2025, Fresenius Medical Care AG employed approximately 110,000 people worldwide (headcount). This figure includes all employees across the group - medical staff, technical and administrative personnel, and all other functions.

Fresenius Medical Care AG went public on October 1, 1996.

The shares of Fresenius Medical Care AG are traded in Germany and the United States:

• Germany: Frankfurt Stock Exchange (Xetra/Prime Standard)
  • Ticker: FME 
  • ISIN: DE0005785802 
  • WKN: 578580 
• USA: As American Depositary Receipts (ADR) on the New York Stock Exchange (NYSE) 
  • Ticker: FMS 
  • ISIN (ADR): US3580291066 
  • CUSIP: 358029106

For the 2024 fiscal year, the Annual General Meeting on May 22, 2025, approved a dividend of €1.44 per share. Payment to shareholders was made starting May 27, 2025.

The entitlement to a dividend is solely linked to the shareholder status on the date of the resolution on the allocation of distributable profit by the Annual General Meeting.

In Germany, dividends are subject to a 25% withholding tax plus a solidarity surcharge (5.5% of the withholding tax, totaling approx. 26.375%) and, if applicable, church tax depending on the individual’s tax situation.

For foreign shareholders, effective taxation may differ depending on double taxation agreements.

Fresenius Medical Care launched a share buyback program in August 2025.

Under this program, up to 29.29 million shares are to be repurchased for a total amount of up to €1 billion. The repurchase is carried out in two tranches.

The first tranche started on August 11, 2025, and was completed on December 29, 2025. The second tranche … and will be concluded by … Fresenius Medical Care regards share buybacks as a part of its capital allocation framework to return excess capital – besides an attractive divided – to shareholders.

Further information can be found here.

The next Annual General Meeting of Fresenius Medical Care AG is scheduled for Thursday, May 21, 2026. The General Meeting is held as a in-person meeting in the Congress Center Messe Frankfurt, Germany.

The AGM is partly broadcast to the public and can be partly followed by interested parties and shareholders. The opening remarks of the Chairman of the Supervisory Board and the CEO’s speech can be followed live in video and audio here.

In principle, shareholders of Fresenius Medical Care AG can attend the AGM and exercise their shareholder rights, either in person, through a proxy, or via a company-appointed proxy representative.

Participation generally requires timely registration and proof of share ownership as specified in the invitation.

All relevant AGM documents, including the invitation, agenda, reports, and voting results, are published here. Key documents are also published in the German Federal Gazette (Bundesanzeiger).

Fresenius Medical Care focuses its sustainability efforts on three core areas: Environmental, Social, and Governance (ESG). Key priorities include:

• Quality and access to healthcare worldwide
• Attractive working conditions and employee development
• Reduction of environmental impact (e.g., emissions, energy efficiency, sustainable sourcing)
• Ethical and responsible business practices

These aspects reflect the company’s long-term strategy to integrate sustainability into daily operations and achieve measurable progress.

Further information can be found here.

Fresenius Medical Care is regularly assessed by independent ESG rating agencies. Further information on indices and ratings is available here.

Corporate Governance refers to the rules and processes governing the management, supervision, and transparency of a company. These structures are shaped by legal requirements, market mechanisms, and internal policies.

Fresenius Medical Care defines good corporate governance as responsible and transparent management aimed at long-term value creation. Our Corporate Governance Statement can be found here.

Management Board compensation is based on a system approved by the AGM and reviewed regularly. Details are disclosed in the company’s remuneration report.

Supervisory Board members receive fixed compensation in accordance with the company’s Articles of Association and AGM resolutions.

The latest annual report is available here.

All annual and quarterly reports are available in the Investor Relations section under “Publications.”

Fresenius Medical Care prepares its financial statements in accordance with IFRS as adopted by the EU. Reporting currency is the Euro.

Upcoming reporting dates are published in the Investor Relations section, including a financial calendar.

Investor presentations (in English only) are published alongside quarterly and annual reports in the Investor Relations section under "Publications."

An ADR (American Depositary Receipts) is a negotiable U.S. certificate representing ownership of shares in a non-U.S. corporation. Two ordinary ADRs correspond to one ordinary share of Fresenius Medical Care. 

U.S. investors often favor ADRs over purchasing shares directly in a company’s home market, as ADRs are traded, cleared, and settled in line with U.S. market standards. A key benefit of ADRs is that they simplify investment in foreign securities and support international portfolio diversification. In addition, ADRs make it easier to compare foreign companies with domestic peers and provide access to pricing and trading information when listed. ADR holders are entitled to all dividends, which will be distributed in U.S. dollars. Other distributions and rights pertaining to the underlying Fresenius Medical Care shares will be made available to ADR holders if applicable. 

Fresenius Medical Care ADRs are traded on the NYSE in the same fashion as U.S. stock. The ADRs can be purchased similar to any other U.S.-traded stocks, either via a broker or by enrolling in the BNY Mellon’s Global BuyDIRECT plan, a direct stock purchase and dividend reinvestment plan.

BNY Mellon Shareowner Services
P.O. Box 43006
Providence RI 02940-3078

Email: shrrelations(at)cpushareownerservices.com

Website: www.mybnymdr.com

Tel.: +1 888-269-2377 (toll-free number in the U.S.)

Tel.: +1 201 680 6825 (international)